News | 22 September 2026
Hikal enters personal care market with new Panoli facility
The facility has commenced commercial production recently, and successfully manufactured its first production batches
The facility has commenced commercial production recently, and successfully manufactured its first production batches
The Process Intensification Training Center in Dublin will provide hands-on training and knowledge-sharing for the biopharmaceutical industry
These prospective studies provide additional evidence that VRAYLAR can help patients achieve meaningful improvements in depressive symptoms, functioning and other patient-centered outcomes in routine clinical practice
The CHMP recommendation is based on results from the Phase III OPERETTA 2 study
The partnership brings together capabilities spanning lipid excipients, shielding polymers, nanoformulation and cGMP manufacturing
H. pylori infection is associated with chronic gastritis and peptic ulcer disease and is recognised as an important risk factor for gastric cancer
At the CII Pharma & Lifesciences Summit 2026, industry and government leaders put regulatory reform, biopharma innovation and AI at centre of India’s pharma agenda
The results showed that clinical responses continued to improve from Week 16 through Week 52 and were maintained through Week 104 among patients receiving Sotyktu
Summit happening on September 24 to bring together healthcare, pharma and biotech leaders to discuss GCCs, genomics, biotechnology and India’s evolving role in global life sciences
Royalty-free licence to support manufacturing readiness, technology transfer and future supply planning in licensed markets
The treatment also produced significant changes across several blood-lipid measures
Leading experts to discuss challenges associated with complex therapeutics, including peptides, oligonucleotides and long-acting injectables at Peptides & Complex Generics Symposium 2026 in Mumbai on September 28–29, 2026
Company shares its capabilities across R&D, complex medicines and biosimilars following the acquisition of Kashiv Biosciences
The experimental therapy is designed to target T cells and two tumour-associated antigens simultaneously
The deal will also transfer three Sanofi manufacturing facilities to Cheplapharm: Csanyikvölgy in Hungary, Jurong in Singapore and Ploërmel in France
Ozone Shield provides security assistance, legal assistance and emotional wellbeing support to doctors in case they get caught in such an untoward scenario
The drug acts through a unique dual mechanism of action, selectively inhibiting the persistent sodium current that drives repetitive neuronal firing
Transfer of API and intermediates business to RPG Active Pharma effective September 16, 2026
Collaboration will focus on QurCan’s non-viral delivery platform, with potential milestone payments of up to $237 million per programme
VitiPure portfolio targets pharmacopoeia-grade, low-endotoxin and stability-critical applications, while US facility strengthens regional PEG supply
Subscribe To Our Newsletter & Stay Updated
